Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.84%
1,092.16
+9.12
+0.84%
—1,083.041,082.631,092.691,080.59——
SIXC
Communications
SIXC
Communications
SIXC
-0.16%
601.42
-0.96
-0.16%
—602.38602.38602.38599.75——
SIXE
Energy
SIXE
Energy
SIXE
+0.09%
1,243.95
+1.12
+0.09%
—1,242.831,229.311,245.581,220.51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.18%
1,751.15
+37.33
+2.18%
—1,713.821,715.471,751.671,715.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.21%
641.32
+1.33
+0.21%
—639.99636.98641.72631.81——
SIXR
Staples
SIXR
Staples
SIXR
+1.61%
850.92
+13.46
+1.61%
—837.46840.30851.69840.30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.92%
216.20
+1.98
+0.92%
—214.22214.22216.39214.05——
SIXT
Technology
SIXT
Technology
SIXT
-1.02%
3,171.72
-32.66
-1.02%
—3,204.383,215.043,215.043,161.16——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.18%
945.57
+20.19
+2.18%
—925.38927.91946.89927.91——
SIXV
Health care
SIXV
Health care
SIXV
+1.98%
1,471.68
+28.53
+1.98%
—1,442.711,443.011,472.821,443.01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.15%
2,364.97
+3.63
+0.15%
—2,361.342,391.002,395.822,354.52——
Q1 2026 earnings • released • EPS miss -4.54% • Revenue beat +0.33%
See results
N1VS34:BVMF
Novartis AG Bdr
R$73.71
+2.73%
(+1.96) 1D
Apr 30, 10:10:20 AM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1VS34...
Open
R$73.71
High
R$73.71
Low
R$73.71
Mkt. cap
302.30B
Avg. vol.
77.00
Volume
1.00
52-wk high
R$87.30
52-wk low
R$61.08
Shares outstanding
2.03B
No. of employees
75K
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG Bdr
CEOVasant Narasimhan
Employees75.3K
FoundedFeb 29, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Last report
Apr 28, 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
1.99/ (2.08 est.)USD
-4.54%miss
Revenue / Estimate
13.52B/ (13.48B est.)USD
+0.33%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
14.84B
14.36B
13.86B
13.52B
Cost of goods sold
3.32B
3.54B
3.54B
-
Cost of revenue
3.32B
3.54B
3.54B
-
Research and development expenses
2.62B
2.86B
2.84B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.44B
3.30B
3.44B
-
Operating expense
6.05B
6.24B
6.46B
-
Total operating expenses
9.37B
9.77B
10.00B
-
Operating income
5.46B
4.58B
3.86B
-
Other non operating income
-13.00M
-7.00M
-130.00M
-
EBT including unusual items
4.53B
4.20B
3.22B
-
EBT excluding unusual items
5.16B
4.29B
3.49B
-
Income tax expense
507.00M
266.00M
814.00M
-
Effective tax rate
11.19%
6.34%
25.30%
-
Other operating expenses
-4.00M
70.00M
190.00M
-
Net income
4.04B
3.93B
2.41B
-
Net profit margin
27.24%
27.36%
17.38%
-
Earnings per share
2.42
2.25
2.03
1.99
Interest and investment income
-
-
373.00M
-
Interest expense
-289.00M
-281.00M
-304.00M
-
Net interest expenses
-289.00M
-281.00M
69.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
6.56B
5.78B
4.96B
-
Gain or loss from assets sale
-67.00M
81.00M
80.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer